US › Healthcare

Chemomab Therapeutics Ltd DRC (CMMB)

US · Healthcare · Biotechnology

$1.68+3.70%

Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue

Net profit

$-1.8M

Profit YoY

+46.6%

EPS

$-0.00

EPS estimate

$0.00

Key statistics

Market cap

$11.4M

Forward P/E

12.9

P/B

1.06

Book value

$1.49

EPS (TTM)

$-1.12

52-week high

$4.12

52-week low

$1.35

50-day MA

$1.71

200-day MA

$1.94

Beta

0.64

Analyst view

Analysts rate Chemomab Therapeutics Ltd DRC a strong buy (2 buy, 0 hold, 0 sell out of 2) with an average price target of $5.00.

Shareholding

Insiders

11.09%

Institutions

7.86%

Largest institutional holders

Fund	Stake
Advisory Services Network, LLC	0.00%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Chemomab Therapeutics Ltd DRC — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Novo Nordisk A/S Amgen Inc Abbott Laboratories Gilead Sciences Inc

Data updated 2026-08-05.